Marekani - Kiingereza - NLM (National Library of Medicine)

par pharmaceutical - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hydrochloride 10 mg - oxycodone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)] , reserve oxycodone hydrochloride tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): - have not been tolerated or are not expected to be tolerated, - have not provided adequate analgesia or are not expected to provide adequate analgesia. oxycodone hydrochloride tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.3)] -   acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment or hypercarbia [see warnings and precautions (5.7)] -   known or suspected gastrointestinal obstruction, including paralytic ileus

Marekani - Kiingereza - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hydrochloride 100 mg in 5 ml - oxycodone hydrochloride oral solution is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, [see warnings and precautions (5.2)] , reserve oxycodone hydrochloride oral solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: oxycodone hydrochloride oral solution is contraindicated in patients with: risk summary prolonged use of opioid analgesics during pregnancy may cause neonatal opioid withdrawal syndrome [see warnings and precautions (5.4)] . available data with oxycodone hydrochloride oral solution are insufficient to inform a drug-associated risk for major birth defects and miscarriage. animal reproduction studies with oral administrations of oxycodone hydrochloride in rats and rabbits during the period of organogenesis at doses 2.6 and 8.

Marekani - Kiingereza - NLM (National Library of Medicine)

physicians total care, inc. - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570), oxycodone terephthalate (unii: m04xwv43uf) (oxycodone - unii:cd35pmg570), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e) - oxycodone hydrochloride 4.5 mg - oxycodone and aspirin tablets are indicated for the management of moderate to moderately severe pain. oxycodone and aspirin tablets are contraindicated in patients with known hypersensitivity to oxycodone or aspirin, and in any situation where opioids or aspirin are contraindicated. aspirin is contraindicated for patients with hemophilia. reye’s syndrome: aspirin should not be used in children or teenagers for viral infections, with or without fever, because of the risk of reye’s syndrome with concomitant use of aspirin in certain viral illnesses. allergy: aspirin is contraindicated in patients with known allergy to nonsteroidal anti-inflammatory drug products and in patients with the syndrome of asthma, rhinitis, and nasal polyps. aspirin may cause severe urticaria, angioedema, or bronchospasm (asthma). oxycodone is contraindicated in patients with known hypersensitivity to oxycodone. oxycodone is contraindicated in any situation where opioids are contraindicated including patients with significa

Marekani - Kiingereza - NLM (National Library of Medicine)

atlantic biologicals corps - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hydrochloride 100 mg in 5 ml - oxycodone hydrochloride solution usp, 100 mg per 5 ml ( ) is an opioid analgesic indicated for the management of moderate to severe acute and chronic pain in opioid-tolerant patients. oral 20 mg/ml oxycodone hydrochloride oral solution usp, 100 mg per 5 ml (20 mg/ml) may cause fatal respiratory depression when administered to patients not previously exposed to opioids. patients considered to be opioid tolerant are those who are taking at least 30 mg of oral oxycodone per day, or at least 60 mg oral morphine per day, or at least 12 mg hydromorphone per day, or an equianalgesic dose of another opioid, for a week or longer. oxycodone hydrochloride oral solution usp is contraindicated in patients with respiratory depression in the absence of resuscitative equipment. oxycodone hydrochloride oral solution usp is contraindicated in any patient who has or is suspected of having paralytic ileus. oxycodone hydrochloride oral solution usp is contraindicated in patients with acute or severe br

Marekani - Kiingereza - NLM (National Library of Medicine)

bryant ranch prepack - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hydrochloride 5 mg - oxycodone hydrochloride capsule is an opioid analgesic, indicated for the management of moderate to severe acute and chronic pain where use of an opioid analgesic is appropriate. oxycodone hydrochloride is contraindicated in patients with respiratory depression in the absence of resuscitative equipment. oxycodone hydrochloride is contraindicated in any patient who has or is suspected of having paralytic ileus. oxycodone hydrochloride is contraindicated in patients with acute or severe bronchial asthma or hypercarbia. oxycodone hydrochloride is contraindicated in patients with known hypersensitivity to oxycodone, oxycodone salts, or any components of the product. pregnancy category b: there are no adequate and well-controlled studies of oxycodone use during pregnancy. based on limited human data in the literature, oxycodone does not appear to increase the risk of congenital malformations. because animal reproduction studies are not always predictive of human response, oxycodone should be used during pregnancy

Marekani - Kiingereza - NLM (National Library of Medicine)

major pharmaceuticals - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hydrochloride 20 mg in 1 ml - oxycodone hydrochloride oral solution is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, [see warnings and precautions (5.2)], reserve oxycodone hydrochloride oral solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: • have not been tolerated, or are not expected to be tolerated, • have not provided adequate analgesia, or are not expected to provide adequate analgesia oxycodone hydrochloride oral solution is contraindicated in patients with: • significant respiratory depression [see warnings and precautions (5.3)] • acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.7)] • known or suspected gastrointestinal obstruction, including paralytic ileus [see wa

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 10 mg - tablet, modified release - excipient ingredients: macrogol 8000; ethylcellulose; titanium dioxide; hyprolose; hypromellose; colloidal anhydrous silica; lactose; magnesium stearate - apo-oxycodone mr modified release tablets are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long-term treatment. apo-oxycodone mr is not indicated for the use in chronic non-cancer pain other than in exceptional circumstances. apo-oxycodone mr is not indicated as an as-needed (prn) analgesia.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 20 mg - tablet, modified release - excipient ingredients: iron oxide red; hyprolose; macrogol 8000; titanium dioxide; colloidal anhydrous silica; lactose; ethylcellulose; hypromellose; magnesium stearate - apo-oxycodone mr modified release tablets are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long-term treatment. apo-oxycodone mr is not indicated for the use in chronic non-cancer pain other than in exceptional circumstances. apo-oxycodone mr is not indicated as an as-needed (prn) analgesia.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 15 mg - tablet, modified release - excipient ingredients: hypromellose; hyprolose; macrogol 8000; colloidal anhydrous silica; titanium dioxide; ferrosoferric oxide; lactose; iron oxide red; magnesium stearate; ethylcellulose - apo-oxycodone mr modified release tablets are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long-term treatment. apo-oxycodone mr is not indicated for the use in chronic non-cancer pain other than in exceptional circumstances. apo-oxycodone mr is not indicated as an as-needed (prn) analgesia.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 30 mg - tablet, modified release - excipient ingredients: magnesium stearate; iron oxide yellow; hyprolose; hypromellose; iron oxide black; colloidal anhydrous silica; lactose; titanium dioxide; macrogol 8000; iron oxide red; ethylcellulose - apo-oxycodone mr modified release tablets are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long-term treatment. apo-oxycodone mr is not indicated for the use in chronic non-cancer pain other than in exceptional circumstances. apo-oxycodone mr is not indicated as an as-needed (prn) analgesia.